智通财经APP获悉，歌礼制药-B(01672)涨超3%，近一个月股价累计涨幅超1倍。截至发稿，涨3.49%，报18.36港元，成交额1.42亿港元。
消息面上，8月15日，歌礼制药-B发布截至2025年6月30日止6个月的中期业绩，该集团取得收入总额人民币1.04亿元(单位下同)，同比增加111.4%；研发成本1.47亿元，同比增加10.9%；公司权益股东应占亏损8795.1万元，同比减少32.5%；每股亏损9.14分。
于报告期内及直至本公告日期，本集团在代谢性疾病管线、免疫性疾病管线及拓展性适应症产品管线方面取得重大进展：ASC30每日一次口服片治疗肥胖症：在美国Ib期研究中，经28天治疗后，经安慰剂校准后的相对基线的平均体重下降高达6.5%，证明其有望成为治疗肥胖症的同类最佳候选药物。
本集团开展美国IIa期研究并于仅一月余内迅速完成125名受试者入组；ASC30每月一次或更低频次皮下注射治疗肥胖症：在美国Ib期研究中，单次皮下注射后在肥胖症患者中表现出36天半衰期，支持每月一次或更低频次给药。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.